Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and Immunogenicity of Ad5-EBOV in Healthy Adults
NCT02326194Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad5-EBOV in Ebola virus disease (EVD) (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Occurrence of adverse reactions after vaccination at 7 days, Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV) at 28 days and 1 more. Started Dec 2014; status: completed.
02
Drugs
Ad5-EBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02326194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326194.